Nurix Therapeutics, Inc. (NASDAQ:NRIX), a biopharmaceutical company specializing in protein degradation therapies, has been making waves in the biotechnology sector with its innovative approach to ...
In a report released today, Jeet Mukherjee from BTIG maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report), with a price target of $35.00. Jeet Mukherjee has given his Buy ...
Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) is expected to announce its earnings results on Thursday, February 20th.
Nurix Therapeutics Inc is a biopharmaceutical company ... treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine ...
DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...
Continued pipeline advancement of strategic collaborations ... compared to $295.3 million as of November 30, 2023. About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage ...
Nurix Therapeutics, Inc. (Nasdaq ... Strengthened balance sheet to support development of pipeline: Nurix ended its fiscal year with an estimated, unaudited $609.6 million in cash and investments ...
Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
About Nurix Therapeutics, Inc. Nurix Therapeutics is a clinical stage ... Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein ...
Several brokerages have updated their recommendations and price targets on shares of Nurix Therapeutics (NASDAQ: NRIX) in the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback